RxDoctor Payments DataLook up a doctor →

Mithun Chakravarthy, MD

Interventional Cardiology · Pittsburgh, PANPI 1053606707

Payments from drug & device makers

$79,017in general payments, 2019–2025

Across 568 payments — averaging $139.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$44K
  • EKOS Corporation$8K
  • Abbott$6K
  • Abiomed$5K
  • Boston Scientific$4K
  • Shockwave Medical, Inc$2K
  • plus $10K from 34 others

What the payments were for

  • Speaking & faculty fees$3,00014%
  • Travel & lodging$4,47521%
  • Food & beverage$13,89365%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,017 in reported general payments places this provider in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$97,186
Medicare patients
215
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$14,046
Repatha SureclickEvolocumab21$12,446
JardianceEmpagliflozin19$11,990
EntrestoSacubitril/Valsartan19$8,688
Rosuvastatin Calcium47$964
Valsartan17$801
Potassium Chloride40$687
Metoprolol Succinate67$576
Atorvastatin Calcium63$541
Bumetanide18$409
Ezetimibe13$402
Losartan Potassium20$218
Metoprolol Tartrate32$215
Warfarin Sodium13$181
Isosorbide Mononitrate ErIsosorbide Mononitrate13$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$243$14,04612 claims
Boehringer IngelheimJardiance$374$11,99019 claims
NovartisEntresto$535$8,68819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →